Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors.
Ani S BalmanoukianJeffrey R InfanteRaid AljumailyAung NaingAshish V ChintakuntlawarNaiyer A RizviHelen J RossMichael GordonPhilip R MallinderNairouz ElgeioushiIgnacio González-GarcíaNathan StandiferJennifer CannNicholas DurhamShahram RahimianRakesh KumarCrystal S DenlingerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
MEDI1873 showed acceptable safety up to 500 mg i.v. every 2 weeks with pharmacodynamics activity, and prolonged SD in some patients. However, further development is not planned because of lack of demonstrated tumor response.